-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[ Focus on Chemical Machinery Equipment Network ] The biomedical industry is one of the seven strategic emerging industries identified by China.
With the steady progress of the Healthy China goal, the domestic demand for high-quality medicines continues to grow, the scale of the biopharmaceutical industry continues to expand, batches of drugs continue to rise, and innovation capabilities continue to improve.
Data show that in 2019, the scale of my country's biomedicine market has exceeded 350 billion yuan, and the scale of the industry now ranks third.
Entering 2021, the state and local governments will pay more attention to the development of the biopharmaceutical industry.
Among them, my country’s "14th Five-Year Plan" and the 2035 long-term goal proposal mentioned that the development of the biopharmaceutical industry will be promoted, and the development of chemical raw materials and bio Biomedicine industry such as traditional Chinese medicine and Mongolian medicine.
With the continuous optimization of the policy environment, the entire industry will press the development "accelerator".
Chemical machinery and equipment network hotspots pay attention to chemical machinery and equipmentWith the steady progress of the Healthy China goal, the domestic demand for high-quality medicines continues to grow, the scale of the biopharmaceutical industry continues to expand, batches of drugs continue to rise, and innovation capabilities continue to improve.
Data show that in 2019, the scale of my country's biomedicine market has exceeded 350 billion yuan, and the scale of the industry now ranks third.
Entering 2021, the state and local governments will pay more attention to the development of the biopharmaceutical industry.
Among them, my country’s "14th Five-Year Plan" and the 2035 long-term goal proposal mentioned that the development of the biopharmaceutical industry will be promoted, and the development of chemical raw materials and bio Biomedicine industry such as traditional Chinese medicine and Mongolian medicine.
With the continuous optimization of the policy environment, the entire industry will press the development "accelerator".
The industry believes that with the support of many factors, the development prospects of the biomedical industry are worthy of recognition, but the industry is also facing some "troubles" as the industry grows, such as lack of key equipment and lack of talents.
These problems will be the high quality of the biomedical industry.
The "blockers" on the road to development require attention and breakthroughs.
These problems will be the high quality of the biomedical industry.
The "blockers" on the road to development require attention and breakthroughs.
"Growth troubles"
"Growth troubles" One is the lack of key equipment.
The supply chain of China's biopharmaceutical industry is complex, mainly involving four links: research and development, production, circulation, and use.
The upstream is mainly APIs, biological raw materials, Chinese medicinal materials, equipment and consumables, etc.
; the midstream includes chemical medicines, biological medicines and traditional Chinese medicines; The downstream is the medical circulation channel.
The supply chain of China's biopharmaceutical industry is complex, mainly involving four links: research and development, production, circulation, and use.
The upstream is mainly APIs, biological raw materials, Chinese medicinal materials, equipment and consumables, etc.
; the midstream includes chemical medicines, biological medicines and traditional Chinese medicines; The downstream is the medical circulation channel.
It is understood that the key instruments and equipment and consumables required for the upstream R&D and industrialization of the domestic biomedical industry chain are mainly dependent on imports, especially European and American equipment.
In addition, some domestic core equipment is still limited by people.
Greatly hinder the pace of high-quality development of the biomedical industry.
In addition, some domestic core equipment is still limited by people.
Greatly hinder the pace of high-quality development of the biomedical industry.
The second is the lack of technical personnel.
At present, my country's biomedicine is gradually developing, and the proportion of biomedicine research and development expenditure has increased by more than 30% in the five years.
It is expected that the general trend of domestic biomedicine research and development will continue to be maintained in the next ten years.
In this context, the demand for technical talents in the medical field will continue to be strong.
At present, my country's biomedicine is gradually developing, and the proportion of biomedicine research and development expenditure has increased by more than 30% in the five years.
It is expected that the general trend of domestic biomedicine research and development will continue to be maintained in the next ten years.
In this context, the demand for technical talents in the medical field will continue to be strong.
However, from the current point of view, there is a considerable shortage of technical talents in the field of medicine and biology in my country, especially for original drug research and development talents.
"The main reason is that in the past, my country's biomedical companies mainly relied on imitations.
There were few new drugs with independent intellectual property rights, and the overall R&D technology was not high.
This phenomenon is actually caused by a shortage of talents.
" .
In the case of a shortage of talents, pharmaceutical companies have stagnated in their R&D progress and cannot achieve technological breakthroughs, severely restricting the sound development of the entire industry.
"The main reason is that in the past, my country's biomedical companies mainly relied on imitations.
There were few new drugs with independent intellectual property rights, and the overall R&D technology was not high.
This phenomenon is actually caused by a shortage of talents.
" .
In the case of a shortage of talents, pharmaceutical companies have stagnated in their R&D progress and cannot achieve technological breakthroughs, severely restricting the sound development of the entire industry.
How to solve it?
How to solve it? So, in the face of the two major bottlenecks in industrial development, how can industry companies break through? In response to the lack of key equipment, the biopharmaceutical industry is moving towards high-quality development, and the requirements for purification processes and equipment will become higher and higher, especially for the structural parameters, process parameters, and control methods of biopharmaceutical equipment .
Will put forward higher requirements.
In this context, domestic pharmaceutical machinery companies need to be good at summing up experience, increase R&D efforts, continue to break through core technologies, create high-cost biomedical equipment, and accelerate domestic substitution of imports.
Pharmaceutical equipment Will put forward higher requirements.
In this context, domestic pharmaceutical machinery companies need to be good at summing up experience, increase R&D efforts, continue to break through core technologies, create high-cost biomedical equipment, and accelerate domestic substitution of imports.
It is understood that there is a biological reactor vendors will be based on * study abroad on the basis of the bioreactor, fully absorb the experience in automatic bioreactor industry, according to China's national conditions and * a survey of market demand, the development of the technology and standards, A medium-series complete set of biological fermentation tanks with high cost performance suitable for domestic use.
At the same time, under the premise of ensuring the stable operation of the fermentation tank, the company has made great efforts to innovate, optimize the equipment and technology, and better meet the needs of pharmaceutical companies.
reactor At the same time, under the premise of ensuring the stable operation of the fermentation tank, the company has made great efforts to innovate, optimize the equipment and technology, and better meet the needs of pharmaceutical companies.
Technical talents master key technologies, which are the core competitive factors of enterprises, which can help enterprises transform technologies into finished products and enhance their market development capabilities.
In the face of the shortage of technical talents, some analysts believe that it is mainly caused by the shortage of funds for small and medium-sized enterprises, or the failure of graduates to meet the employment requirements of enterprises.
Therefore, it is necessary to "prescribe the right medicine".
In terms of funding, more policy support is needed; in terms of employment, it is necessary to start from the source of talent training, improve the traditional talent training model, innovate the talent training model that combines production, education and research, and explore countermeasures that are in line with the development of my country's biomedical industry.
In the face of the shortage of technical talents, some analysts believe that it is mainly caused by the shortage of funds for small and medium-sized enterprises, or the failure of graduates to meet the employment requirements of enterprises.
Therefore, it is necessary to "prescribe the right medicine".
In terms of funding, more policy support is needed; in terms of employment, it is necessary to start from the source of talent training, improve the traditional talent training model, innovate the talent training model that combines production, education and research, and explore countermeasures that are in line with the development of my country's biomedical industry.
It is reported that many regions have also made innovative attempts in talent training.
For example, through university alliances, to impart R&D experience to students, and at the same time help settled companies absorb university graduate students to join the new drug research and development team, and realize the resource sharing of enterprises, universities, and scientific research institutions.
Facilitate the cultivation of biomedical research and development talents.
For example, through university alliances, to impart R&D experience to students, and at the same time help settled companies absorb university graduate students to join the new drug research and development team, and realize the resource sharing of enterprises, universities, and scientific research institutions.
Facilitate the cultivation of biomedical research and development talents.
Concluding remarks
Concluding remarks At present, the domestic biomedical industry is showing a vigorous development trend.
In order to seize the development opportunities, industry enterprises should make forward-looking layouts, continue to make up for the shortcomings in key equipment and talents, and do a good job in "strong chain" and "chain extension".
Supplement the chain” and establish a good industrial ecosystem.
Domestic biomedical equipment companies should take advantage of the east wind, continuously improve the level of innovative research and development, accelerate the realization of localized replacement of equipment, and promote the development of higher quality in the biomedical industry.
In order to seize the development opportunities, industry enterprises should make forward-looking layouts, continue to make up for the shortcomings in key equipment and talents, and do a good job in "strong chain" and "chain extension".
Supplement the chain” and establish a good industrial ecosystem.
Domestic biomedical equipment companies should take advantage of the east wind, continuously improve the level of innovative research and development, accelerate the realization of localized replacement of equipment, and promote the development of higher quality in the biomedical industry.
Original title: The biomedical industry is facing "growth troubles": lack of key equipment and shortage of talents
